GUBamy – Talk Bio

Actionable Insights Powered by AI

AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog

2 months ago talkbio0Tagged AbbVie, Amylin Analog, GUB014295, GUBamy, Gubra, Obesity, pharmaceutical licensing, Weight-Loss Agents

AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

5 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist